Oral GIP/GLP-1 Peptide Tablets Achieve Higher Bioavailability Than Oral Semaglutide in Monkeys
Erodible tablets with SNAC permeation enhancer achieved 4.2% oral bioavailability for a GIP/GLP-1 dual agonist peptide — 3.5× higher than semaglutide (1.2%) — through improved pepsin stability and optimized release kinetics.
Quick Facts
What This Study Found
GIP/GLP-1 dual agonist peptide with higher pepsin stability achieved 4.2% oral bioavailability via SNAC erodible tablets vs 1.2% for semaglutide, a 3.5-fold improvement.
Key Numbers
Two permeation enhancers tested (C10 and SNAC); erodible tablet formulation; tested in monkeys for gastric delivery of a GIP/GLP-1 peptide.
How They Did This
Development and in vivo evaluation of C10 and SNAC erodible tablets in cynomolgus monkeys, with tissue distribution studies, release kinetics optimization, and comparison to oral semaglutide bioavailability.
Why This Research Matters
Oral peptide delivery could eliminate the need for injections of GLP-1 medications. This study shows that combining improved peptide stability with optimized tablet formulation can dramatically improve oral absorption — potentially leading to more effective oral obesity and diabetes pills.
The Bigger Picture
Oral semaglutide (Rybelsus) was a breakthrough but absorbs poorly (1-2%). This work shows next-generation peptides designed for oral delivery could achieve much higher absorption, potentially enabling lower doses with better efficacy for obesity and diabetes treatment.
What This Study Doesn't Tell Us
Monkey data may not directly predict human bioavailability; absolute bioavailability still low (<6%); single-dose study without chronic dosing; only one peptide compared to semaglutide; gastric variability (pH, motility) not fully explored; LY peptide not yet clinically available.
Questions This Raises
- ?Can the 4.2% bioavailability be further improved with next-generation formulations?
- ?How does the LY peptide's efficacy compare to injectable GLP-1 agonists at achievable oral doses?
- ?Will these formulation principles translate to improved oral bioavailability in humans?
Trust & Context
- Key Stat:
- 4.2% vs 1.2% oral bioavailability of GIP/GLP-1 peptide vs semaglutide via SNAC tablets in monkeys
- Evidence Grade:
- Preliminary preclinical evidence from a well-designed monkey study with mechanistic tissue analysis. Promising but human translation needed.
- Study Age:
- Published in 2024, representing advances toward next-generation oral peptide medications.
- Original Title:
- Development and evaluation of C10 and SNAC erodible tablets for gastric delivery of a GIP/GLP1 peptide in monkeys.
- Published In:
- International journal of pharmaceutics, 650, 123680 (2024)
- Authors:
- Tran, Huyen, Dogra, Mridula, Huang, Siyuan, Aihara, Eitaro, ElSayed, Mohamed, Aburub, Aktham
- Database ID:
- RPEP-09403
Evidence Hierarchy
Frequently Asked Questions
Could this make GLP-1 pills work better than current oral semaglutide?
Yes — by designing a peptide that resists stomach acid breakdown better than semaglutide and optimizing the tablet formulation, researchers achieved 3.5 times better absorption in monkeys. This could lead to more effective oral obesity and diabetes medications.
How does the oral pill get a peptide through the stomach lining?
The tablets contain a substance called SNAC that helps in two ways: it loosens the junctions between stomach cells (letting the peptide pass between them) and it helps cells absorb the peptide directly through their membranes.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09403APA
Tran, Huyen; Dogra, Mridula; Huang, Siyuan; Aihara, Eitaro; ElSayed, Mohamed; Aburub, Aktham. (2024). Development and evaluation of C10 and SNAC erodible tablets for gastric delivery of a GIP/GLP1 peptide in monkeys.. International journal of pharmaceutics, 650, 123680. https://doi.org/10.1016/j.ijpharm.2023.123680
MLA
Tran, Huyen, et al. "Development and evaluation of C10 and SNAC erodible tablets for gastric delivery of a GIP/GLP1 peptide in monkeys.." International journal of pharmaceutics, 2024. https://doi.org/10.1016/j.ijpharm.2023.123680
RethinkPeptides
RethinkPeptides Research Database. "Development and evaluation of C10 and SNAC erodible tablets ..." RPEP-09403. Retrieved from https://rethinkpeptides.com/research/tran-2024-development-and-evaluation-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.